Patient-Reported Outcomes After Platelet-Rich Plasma, Bone Marrow Aspirate, and Adipose-Derived Mesenchymal Stem Cell Injections for Symptomatic Knee…

Objective:The objective of this study was to compare platelet-rich plasma (PRP), bone marrow aspirate concentrate (BMAC), and adipose-derived mesenchymal stem cell (MSC) injections in the treatment of osteoarthritis (OA) of the knee using functional scores.

Methods:A total of 89 patients with painful knee OA were included in this study. Patients were assigned to one of the 3 treatments according to severity of OA as indicated by symptoms and radiography to PRP (stage I), BMAC (stage II), or adipose-derived MSC (stage III). Clinical assessment was performed using the Knee Society Score, which combines the Knee Score, based on the clinical parameters, and the Functional Score, and IKDC score. Surveys were completed at preoperative and at 90, 180, and 265 days postoperative. The follow-up responses were compared with baseline and between treatment groups.

Results:Treatment with PRP, BMAC, and adipose-derived MSC included 29 (32.6%), 27 (30.3%), and 33 (37.1%) patients, respectively. For the total group, median age was 61 years (range: 22-84 years). Score values were comparable among treatment groups at baseline. Statistically significant improvement was observed in the 3 groups according to the 3 scores at all time points during follow-up compared with baseline. No difference was found among treatment type.

Conclusions:Our findings support previous reports and encourage further research on the use of these cost-effective treatments for OA of the knee.

Keywords:Platelet-rich plasma; adipose-derived mesenchymal stem cell; bone marrow aspirate concentrate; knee; osteoarthritis.

See the original post:
Patient-Reported Outcomes After Platelet-Rich Plasma, Bone Marrow Aspirate, and Adipose-Derived Mesenchymal Stem Cell Injections for Symptomatic Knee...

Post COVID 19 Pandemic Global Canine Stem Cell Therapy Market Research Report 2020 Top Players Include, VETSTEM BIOPHARMA, Cell Therapy Sciences,…

Global Canine Stem Cell Therapy Market analysis 2015-2027, is a research report that has been compiled by studying and understanding all the factors that impact the market in a positive as well as negative manner. Some of the prime factors taken into consideration are: various rudiments driving the market, future opportunities, restraints, regional analysis, various types & applications, Covid-19 impact analysis and key market players of the Canine Stem Cell Therapy market. nicolas.shaw@cognitivemarketresearch.com or call us on +1-312-376-8303.

Download Report from: https://cognitivemarketresearch.com/medical-devicesconsumables/canine-stem-cell-therapy-market-report

Global Canine Stem Cell Therapy Market: Product analysis: Allogeneic Stem Cells, Autologous Stem cells

Global Canine Stem Cell Therapy Market: Application analysis: Veterinary Hospitals, Veterinary Clinics, Veterinary Research Institutes

Major Market Players with an in-depth analysis: VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana Therapeutics, Medivet Biologics, Okyanos, Vetbiologics, VetMatrix, Magellan Stem Cells, ANIMAL CELL THERAPIES, Stemcellvet

The research is presented in such a way that it consists of all the graphical representations, pie charts and various other diagrammatic representations of all the factors that are used for the research. Canine Stem Cell Therapy market research report also provides information on how the industry is anticipated to provide a highly competitive analysis globally, revenues generated by the industry and increased competitiveness and expansions among various market players/companies.

Get A Free Sample of Canine Stem Cell Therapy Market Report: https://cognitivemarketresearch.com/medical-devicesconsumables/canine-stem-cell-therapy-market-report#download_report

The Canine Stem Cell Therapy industry is projected in assembling information regarding dynamic approximations and also listings of a profitable progression rate annually in the expected duration according to a recent & latest study. The latest Coronavirus pandemic impact along with graphical presentations and recovery analysis is included in the Canine Stem Cell Therapy research report. The research report also consists of all the latest innovations, technologies and systems implemented in the Canine Stem Cell Therapy industries.

Various factors with all the necessary limitations, expenditure/cost figures, consumer behaviour, supply chain, government policies and all the information related to the market have been included in the Canine Stem Cell Therapy Market report. The research report also provides light on various companies & their competitors, market size & share, revenue, forecast analysis and all the information regarding the Canine Stem Cell Therapy Market.

Checkout Inquiry for Buying or Customization of Report: https://cognitivemarketresearch.com/medical-devicesconsumables/canine-stem-cell-therapy-market-report#download_report.

Canine Stem Cell Therapy Market research report provides an in-depth analysis of the entire market scenario starting from the basics which is the market introduction till the industry functioning and its position in the market as well as all the projects and latest introductions & implementations of various products. The research study has been assembled by understanding and combining various analysis of regions globally & companies and all necessary graphs and tables that bring the theory into an exact representation through numerical values and standard tables.

The global estimations of the market value, market information/definition, classifications of all the types & applications, overall threats & dips that can be assumed and many other factors which consist the overall market scenario and its happening globally along with the forthcoming years are compiled in the Canine Stem Cell Therapy market research report. Hence this report can serve as a handbook/model for the enterprises/players interested in the Canine Stem Cell Therapy Market as it consists all the information regarding the Canine Stem Cell Therapy market.

Any query? Enquire Here For Discount (COVID-19 Impact Analysis Updated Sample): Click Here> Download Sample Report of Canine Stem Cell Therapy Market Report 2020 (Coronavirus Impact Analysis on Canine Stem Cell Therapy Market)

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19. (*If you have any special requirements, please let us know and we will offer you the report as you want.)

About Us: Cognitive Market Research is one of the finest and most efficient Market Research and Consulting firm. The company strives to provide research studies which include syndicate research, customized research, round the clock assistance service, monthly subscription services, and consulting services to our clients. We focus on making sure that based on our reports, our clients are enabled to make most vital business decisions in easiest and yet effective way. Hence, we are committed to delivering them outcomes from market intelligence studies which are based on relevant and fact-based research across the global market. Contact Us: +1-312-376-8303 Email: nicolas.shaw@cognitivemarketresearch.com Web: https://www.cognitivemarketresearch.com/

**********Download the Entire Report************************************************* https://cognitivemarketresearch.com/medical-devicesconsumables/canine-stem-cell-therapy-market-report

View post:
Post COVID 19 Pandemic Global Canine Stem Cell Therapy Market Research Report 2020 Top Players Include, VETSTEM BIOPHARMA, Cell Therapy Sciences,...

Can banking your stem cells prevent aging? | Well+Good

Ugggghh, getting old sucks!Its something you hear all the time, right? From a 31-year-old, suddenly unable to have two glasses of wine without waking up hungover the next day. A 43-year-old with a bum knee. A 65-year-old who cant remember where she put her keys. And on. And on. And on.

As conventional wisdomhas it, the effects of aging are non-negotiable. Plus, people are living longer than ever, which potentially means more years spent in less-than-optimal condition. But proponents of a new technologystem-cell bankingclaim getting older doesnt have to come with the irreversible downward health spiral weve all been conditioned to expect. Their claim: Storing and eventually re-injecting your own adult stem cells may help your body heal the first signs of age-related disease down the line, keeping you feeling vital longer.

Sounds intriguingbut is it legit?

Heres the deal: Stem cellsare unspecialized cellsthat have the potential to multiply and grow into many different types of cells throughout the body, from bone to muscle to neuron and beyond. By extracting and freezing these repair cells from your own bodybanking them, essentiallythe idea is that when your health starts to decline, you can have them reinserted into your body right at the site of the problem. If you start suffering from arthritis, for example, your stored stem cells would be inserted into your joints so healthy cells will multiply and take over, theoretically eliminating your pain.

One such stem-cell preservation company isForever Labs, which is currently working with physicians in Los Angeles, New York, Miami, Boston, Washington, DC, and more.Forever Labs was born out of our own mid-life crises, says strategic growth expert Steve Clausnitzer, who co-founded the biz with friend and longtime stem-cell researcher Mark Katakowski, PhD.Three years ago, I was turning 40, and I said to Steve, Im convinced that I want to have my young cells later in life, Katakowski says. And he said, You know what? Id like to have that too.

Related Stories

{{ truncate(post.title, 18) }}

Those young cells they were talking about are, of course, stem cells. Doctors are already using these to help the body heal, taking healthy stem cells from a strong part of the body and immediately transplanting them to whatever area new cells are needed. Orthopedic surgeons and sports medicine doctors use bone marrow-derived stem cells to treat injuries, including joint issues and musculoskeletal problems. Theyre regularly used for skin graftsand forcancer patients, replacing blood-formingcellsdestroyed by chemo or radiation.

Armin Tehrany, MD, founder of Manhattan Orthopedic Care(who is unaffiliated with Forever Labs), sees stem-cell therapy as an effective form of treatmentat least in his field of medicinealthough he admits scientists arent exactly sure how or why it works. There are theories that what [stem cells] do is attach to the bodys actual tissue and potentially change the tissue turning those cells on so they become what theyre supposed to be, as opposed to being degenerated part of the tissue, he says.

Banking yourself basically creates a pool of young biology that doesnt experience the wear and tear of life. Steve Clausnitzer, Forever Labs cofounder

Yet, as Katakowski will tell you, one of the sad truths about stem cells is that they lose function as they age. For 17 years, Id been working with bone-marrow stem cells developing treatment for stroke and other neural injuries and diseases, learning firsthand the therapeutic value of the cells, but also that the number of cells and their efficacy is less with age, he explains.

Thats where stem cell banking comes in. Extracting them from your bone marrow or fat stores and cryogenically freezing them while theyre still young and strong is an entirely new concept. (In fact, Forever Labs is the first company thats set on using stem cells to extend human healthspans.) But that may be about to change. Theres been an explosion of clinical application of this knowledgea couple hundred clinical studies at last count,Katakowski says.

Why bank your own stem cells, as opposed to, say, getting them from a younger donor? The short answer is that if you want to replace tissue, you need your own cells, Katakowski says. There is some evidence that you can get some acute benefit using someone elses, but its a short kind of benefit because cells dont stick around. Your body finds them and weeds them out. (Its similar to the way bodies sometimes reject a transplanted organthat means theres no bank-one-for-the-whole-family type of deal.)

Katakowski believes the best time to bank stem cells is between the ages of 20 and 40. That said, he still advises older people to do it, toohis mother banked hers at 70. Dr. Tehrany says its more important to consider your health than actual age when considering any type of stem-cell therapy. Someone can be 75, butphysiologically and genetically be 55, he says. [Conversely,] if someones overall health is declining, its safe to say their stem cell functionality is declining too.

So lets say you buy into this whole freezing-your-stem-cells thing. When, exactly, would you ask for them back? According to Katakowski and Clausnitzer, the time to use them is when you start experiencing undesirable health impacts brought on by aging. This can be caused by something sudden, like having a stroke, or something you notice gradually, like a slow decline in memory. At that point, a doctor would inject your stored stem cells back into the affected body part. (Or partsbecause, lets be honest, aging is a full-body kind of deal.)In theory, the stem cells would then help the not-so-healthy tissue regenerate and become more vital.

Emphasis on the theory part. Since the technology is still so new, its actual success rate is still very much TBD. While Forever Labs has undertaken many encouraging studies with mice, the companys human studiesmore than 700 of themare still underway, and it will take years to see the long-term effects. Dr. Tehrany affirms that this is cutting-edge stuff, and the scientific backup just isnt there yet. But that doesnt mean hes ruling out the stem-cell banking concept. Based on how successful stem cells are as a treatment, I do think its important to respect and value the potential of them as a preventative, he says.

Theres also the lingering thought that maybe youll get lucky and age without any problems at all. Then, wouldnt it be a huge waste of money to pay for decades of stem-cell freezing? (At $2,500 for the procedure and $300 a year for storage, it isnt cheap.) After all, theres tons of emerging research that indicates a healthy diet and regular exercisecan go a long way in preventing age-related declineand those are basically free.(Ah, the boring, yet sound advice thats been preached for decades.)

Clausnitzer personally believes its not wise to play the odds. Theres a lot of evidence that as you get into middle age, all this damage accrues in your cells and a lot of that is irreversible, such as DNA mutations, Clausnitzer says. Banking yourself basically creates a pool of young biology that doesnt experience the wear and tear of life. So what you bank is kind of like the seeds that you can use to grow many, many of your own young stem cells to treat yourself.

Ultimately, no so-called illness-proofing option comes with any guarantees, making the choice a totally personal one. But it does raise the question: If youre 90 years old, but your cells are only 40, how old are you really?

Speaking of longevity, this is the type of exercise thatll add years to your life. Having these personality traits helps, too.

Read more:
Can banking your stem cells prevent aging? | Well+Good

Humanigen Expands Partnership with Catalent Biologics to Manufacture Investigational COVID-19 Therapeutic Candidate Lenzilumab – BioSpace

SOMERSET, N.J. & BURLINGAME, Calif.--(BUSINESS WIRE)-- Catalent and Humanigen, Inc. (HGEN) (Humanigen) today announced the expansion of their relationship, under which Catalent will provide development, manufacturing and commercialization services for lenzilumab, Humanigens proprietary Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200716005256/en/

Catalent is the leading global provider of advanced delivery technologies, development, manufacturing and clinical supply solutions for drugs, biologics, cell and gene therapies and consumer health products. Humanigen is a clinical stage biopharmaceutical company focused on preventing and treating cytokine storm with lenzilumab, the companys lead therapeutic candidate.

Mayo Clinic recently announced data on the first clinical use of lenzilumab in 12 patients with severe and critical COVID-19 pneumonia, the majority of whom showed rapid recovery and hospital discharge. A Phase 3 study is currently underway evaluating hospitalized COVID-19 patients.

Based on lenzilumabs promising clinical data, we are pleased to expand our relationship with Catalent to solidify our ability to manufacture and supply lenzilumab, commented Cameron Durrant, MD, MBA, Chief Executive Officer of Humanigen. If we are able to secure FDA approvals or Emergency Use Authorization, Catalent Biologics deep expertise and integrated OneBio solution will accelerate our ability to get this therapy to patients that need it most.

Catalent has partnered closely with Humanigen to develop and supply lenzilumab for clinical trials, commented Karen Flynn, President of Catalent Biologics and Chief Commercial Officer. The experience we already have with lenzilumab, and our OneBio integrated offering from development to supply, make Catalent uniquely suited to support Humanigen in the journey to make this promising therapy available to COVID-19 patients as soon as possible following receipt of regulatory approvals.

To date, Catalent Biologics has provided early-stage development and clinical cGMP drug substance manufacturing for lenzilumab at its facility in Madison, Wisconsin to support Humanigens ongoing clinical trials across various disease categories. Under the expanded partnership, Catalent is also providing clinical supply support for Humanigens Phase 3 potential registration study in COVID-19 from its Philadelphia facility.

Lenzilumab was originally manufactured in Catalents Madison facility using Catalent Biologics proprietary GPEx cell line development technology. As part of the expanded partnership, Catalent intends to provide additional drug substance clinical supply for Humanigens clinical trials, Expanded Access Program (EAP), as well as additional late-stage development and clinical and potential commercial drug substance manufacturing and vial filling at its Madison and Bloomington, Indiana, sites.

Catalent Biologics Madison facility provides development and drug substance manufacturing, including GPEx cell line development, process development, process validation, formulation development, and clinical and commercial cGMP manufacturing. Its Bloomington facility has deep expertise in sterile formulation, with drug substance development and manufacturing and drug product fill/finish capacity across liquid and lyophilized vials, prefilled syringes, and cartridges as well as primary and secondary packaging.

Catalents OneBio Suite is an integrated solution for the development, manufacturing, and supply of biologic drugs. Launched in May 2019, the suite of offerings is designed to integrate activities and accelerate timelines, reduce risk and simplify development with a single contract, program manager, and development timeline from cell line development to supply, with harmonized quality systems.

About Humanigen, Inc.

Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms. We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection. The companys immediate focus is to prevent or minimize the cytokine release syndrome that precedes severe lung dysfunction and ARDS in serious cases of SARS-CoV-2 infection. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. In addition, the company is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, bispecific or natural killer (NK) T cell engaging immunotherapy treatments to break the efficacy/toxicity linkage, including to prevent and/or treat graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Additionally, Humanigen and Kite, a Gilead Company, are evaluating lenzilumab in combination with Yescarta (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma in a clinical collaboration. For more information, visit http://www.humanigen.com.

About Catalent Biologics

Catalent Biologics is a global leader in development, manufacturing and analytical services for new biological entities, cell and gene therapies, biosimilars, sterile injectables, and antibody-drug conjugates. With over 20 years of proven expertise, Catalent Biologics has worked with 600+ mAbs and 80+ proteins, produced 13 biopharmaceutical drugs using GPEx cell line development technology, and manufactured 35+ commercially approved products. Catalent Cell & Gene Therapy, a unit of Catalent Biologics, is a full-service partner for adeno-associated virus (AAV) vectors and CAR-T immunotherapies, with deep experience in viral vector scale-up and production. Catalent recently acquired MaSTherCell, adding expertise in autologous and allogeneic cell therapy development and manufacturing. Catalent Cell & Gene Therapy has produced 100+ cGMP batches across 70+ clinical and commercial programs. For more information, visit biologics.catalent.com.

About Catalent

Catalent is the leading global provider of advanced delivery technologies, development, manufacturing, and clinical supply solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs over 13,500 people, including over 2,400 scientists and technicians, at more than 40 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com.

More products. Better treatments. Reliably supplied.

Humanigens Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as "will," "expect," "intend," "plan," "potential," "possible," "goals," "accelerate," "continue," and similar expressions identify forward-looking statements, including, without limitation, statements regarding our expectations for the Phase III study and the potential future development of lenzilumab to minimize or reduce the severity of lung dysfunction associated with severe and critical COVID-19 infections or to be approved by FDA for such use or to help CAR-T reach its full potential or to deliver benefit in preventing GvHD. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in our lack of profitability and need for additional capital to conduct the Phase III study and grow our business; our dependence on partners to further the development of our product candidates; the uncertainties inherent in the development and launch of any new pharmaceutical product; the outcome of pending or future litigation; and the various risks and uncertainties described in the "Risk Factors" sections and elsewhere in the Company's periodic and other filings with the Securities and Exchange Commission.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not place undue reliance on any forward-looking statements, which speak only as of the date of this release. We undertake no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200716005256/en/

Visit link:
Humanigen Expands Partnership with Catalent Biologics to Manufacture Investigational COVID-19 Therapeutic Candidate Lenzilumab - BioSpace

Study: Oxygen therapy improves cognitive function in seniors – Mirage News

The Sagol Center for Hyperbaric Medicine and Research at Shamir Medical Center, together with Sackler School of Medicine and Sagol School of Neuroscience at Tel Aviv University announced that, for the first time, in humans, a peer-reviewed study has demonstrated that hyperbaric oxygen therapy (HBOT) can significantly enhance the cognitive performance of healthy older adults.

The main areas of improvement were attention, information processing speed, executive function, in addition to the global cognitive function, all of which typically decline with age. Moreover, there was a significant correlation between the cognitive changes and improved cerebral blood flow in specific brain locations.

The study was published on July 15th, 2020 in the peer reviewed journal Aging, entitled: Cognitive enhancement of healthy older adults using hyperbaric oxygen: a randomized controlled trial.

Professor Shai Efrati, Head of the Sagol Center for Hyperbaric Medicine and Research, and Head of Research & Development at Shamir Medical Center, and an Associate Professor at Sackler School of Medicine and Sagol School of Neuroscience at Tel Aviv University, and Dr. Amir Hadanny, the Sagol Center for Hyperbaric Medicine and Research, designed the study based on a unique HBOT protocol developed at the Sagol Center over the past 10 years. The randomized controlled clinical trial included 63 healthy adults (>64) who underwent either HBOT (n=33) or a control period (n=30) for three months. The studys primary endpoint included a change in general cognitive function measured by a standardized comprehensive battery of computerized cognitive assessments before and after the intervention or control. Cerebral blood flow (CBF) was evaluated by a novel magnetic resonance imaging technique for brain perfusion.

Age-related cognitive and functional decline has become a significant concern in the Western world. Major research efforts around the world are focused on improving the cognitive performance of the so-called normal aging population, said Prof. Efrati. In our study, for the first time in humans, we have found an effective and safe medical intervention that can address this unwanted consequence of our age-related deterioration.

Over years of research, we have developed an advanced understanding of HBOTs ability to restore brain function. In the past, we have demonstrated HBOTs potential to improve/treat brain injuries such as stroke, traumatic brain injury and anoxic brain injury (due to sustained lack of oxygen supply) by increasing brain blood flow and metabolism, explained Dr. Amir Hadanny. This landmark research could have a far-reaching impact on the way we view the aging process and the ability to treat its symptoms.

During HBOT, the patient breaths in pure oxygen in a pressurized chamber where the air pressure is increased to twice that of normal air. This process increases oxygen solubility in the blood that travels throughout the body. The added oxygen stimulates the release of growth factors and stem cells, which promote healing. HBOT has been applied worldwide mostly to treat chronic non-healing wounds.

There is a growing body of evidence on the regenerative effects of HBOT. The researchers have demonstrated that the combined action of delivering high levels of oxygen (hyperoxia) and pressure (hyperbaric environment), leads to significant improvement in tissue oxygenation while targeting both oxygen and pressure sensitive genes, resulting in restored and enhanced tissue metabolism. Moreover, these targeted genes induce stem cell proliferation, reduce inflammation and induce generation of new blood vessels and tissue repair mechanisms.

The occlusion of small blood vessels, similar to the occlusions which may develop in the pipes of an aging home, is a dominant element in the human aging process. This led us to speculate that HBOT may affect brain performance of the aging population, Prof. Efrati explained. We found that HBOT induced a significant increase in brain blood flow, which correlated with cognitive improvement, confirming our theory. One can conjecture that similar beneficial effect of HBOT can be induced in other organs of the aging body. These will be investigated in our upcoming research.

The research group leader, Professor Shai Efrati, who serves as director of The Sagol Center for Hyperbaric Medicine and Research, and is an Associate Professor at Sackler School of Medicine and Sagol School of Neuroscience at Tel Aviv University, also disclosed his role with Aviv Scientific LTD, which has developed a comprehensive program that includes HBOT treatment, cognitive and physical training and nutritional coaching, to enhance brain and body performance of aging adults based on the Sagol HBOT protocol at Aviv Clinics. Prof. Efrati serves as Chair of Aviv Scientifics Medical Advisory Board.

Continued here:
Study: Oxygen therapy improves cognitive function in seniors - Mirage News

Nebraska AG files lawsuit against Omaha stem cell clinic – Lincoln Journal Star

Nebraska Attorney General Doug Peterson on Thursday filed a lawsuit against an Omaha-based stem cell clinic.

The lawsuit, filed in Douglas County District Court, alleges that the Regenerative Medicine & Anti-Aging Institute of Omaha and its owners,Travis and Emily Autor, made more than $2 million by making deceptive and misleading statements to consumers regarding the ability of their stem cell therapy to treat specific diseases and health conditions.

The lawsuit also alleges the clinic misrepresented that stem cell therapy is safe and that larger doses are more effective, without possessing the necessary evidence to make these types of claims.

It seeks to stop the clinic from making deceptive and misleading claims regarding its treatments, to refund money to patients and to pay an undetermined amount of civil penalties.

According to Peterson, the Autors operate a network of companies across the country that advertise and sell stem cell therapy directly to consumers, with clinics also located in Arizona, Florida, Idaho, Montana, Vermont, Virginia and Washington.

Though the Food and Drug Administration has noted stem cells' potential to treat and cure some diseases and medical conditions, the therapy is not FDA-approved. In September, the FDA warned consumers that the unapproved use of stem cell treatments can be particularly unsafe, and may lead to adverse reactions, such as the failure of cells to function as expected and tumor growth.

The rest is here:
Nebraska AG files lawsuit against Omaha stem cell clinic - Lincoln Journal Star

The Oncology Institute Extends Its Reach to Serve an Additional 180000 Patients Through New Contracts and Acquisitions – Business Wire

CERRITOS, Calif.--(BUSINESS WIRE)--The Oncology Institute of Hope and Innovation (TOI), the largest community oncology practice on the West Coast, announced today that it has agreed to care for an additional 180,000 patients through new contracts, strategic partnerships, and practice acquisitions.

TOIs steadfast commitment is to deliver on the promise of value-based care, shared Brad Hively, TOI CEO. We are excited to enter into partnerships with best-in-class payors and providers, utilizing the skills of our vast network of physicians and years of experience to solve the most pressing challenges around cancer care today.

TOI recently entered into three new value-based contracts extending its reach to Los Angeles, Las Vegas, and southern Californias high desert and mountain communities.

In May, TOI acquired the practice of Dr. Manuel Zevallos, a longstanding and well-respected oncologist in Lynwood, CA. Joining TOI was a natural fit for my practice, shared Dr. Zevallos. We share the same evidence-based, patient-first approach. Dr. Zevallos is now practicing from TOIs Lynwood clinic, where he will continuing caring for his patients.

About The Oncology Institute of Hope and Innovation

Founded in 2007, The Oncology Institute of Hope and Innovation (TOI) is the largest community oncology practice on the west coast, and the nations leading value-based oncology services platform. TOI employs 75 physicians and mid-levels in 40 clinic locations, with over 500 total employees helping to deliver cutting edge, evidence-based cancer care to a population of over 1 million patients. TOI brings comprehensive, integrated cancer care into community settings, including Clinical Trials, Palliative Care programs, Stem Cell Transplants, Transfusions, and other care delivery models more traditionally associated with tertiary care settings. For more information visit http://www.theoncologyinstitute.com.

Read the original here:
The Oncology Institute Extends Its Reach to Serve an Additional 180000 Patients Through New Contracts and Acquisitions - Business Wire

Why is this nebula shaped like a butterfly? – Massive Science

Eight years ago, I was packing my home and entire life in Mexico to move to the US to pursue a PhD in Ecology and Evolutionary Biology at the University of California-Irvine. Those were easier times, although it did not seem like it at the time. I spent a few months worth of income to pay for paperwork to apply for an F-1 student visa, and to pay for other documents to enroll as a graduate student. This was after I dedicated months to emailing professors everywhere in the US, hoping that one of them would reply to my email and would invite me to apply to join their lab. It was also after spending time and money paying for standardized tests, official document translations, and application fees. It was a one-and-a-half-year process but in July 2012, I was finally moving to the USA to pursue my PhD. It was a dream come true.

It was also a dream come true for the University of California because I had a full scholarship from my home country that paid for the entirety of my international tuition and fees, which were around $35,000 per year. My scholarship allowed me to pursue my PhD in the USA, and to UC Irvine it provided basically free labor as well as prestige.

I paid taxes and did all of the typical graduate student responsibilities. I also dedicated a lot of my time to doing outreach to bring science to underserved communities around Orange County and Southern California. By the time I graduated in 2017, I was a stellar student, with three publications with UC Irvine's name on them. I co-organized summer science camps for middle school girls that brought money and a good reputation to my university and program. I mentored students of all ages. I was a good citizen of my program, of my university, and of Orange County.

Like me, most international students leave their families and everything that they are comfortable with to pursue the dream of graduate school. They bring with them the hope of being welcomed and treated fairly by their American peers. I have experienced this, but I am one of the lucky ones.

It is no secret that international students and postdocs will withstand abuse and other injustices just so they can keep their visa, which is always tied to their university. Many universities receive international students without having a system to deal with the unique challenges that international students face, such as having no credit history, which complicates finding a place to live and leaves international students vulnerable to landlord abuse. Many international students are people of color, and universities, especially predominantly white institutions, do not have resources to ensure safety of these students within the university and in the community at large.

These challenges are further complicated due to a lack of community and support. Making friends in the US, especially if you are coming from Global South countries and/or non-Westernized countries, is extremely challenging. Many times, I have seen how western Europeans, Australians, and Canadians are rapidly accepted in the local community, while many Latinx, Asians, and Middle-Easterners are not.

There are over one million international students in the US. The ICE Student Ban may no longer be a threat, but universities still need to change how they handle international students. We are people too, but many universities have historically valued us only by the amount of money we bring. We improve higher education not only by the money that we bring, but by our unique perspectives, our research productivity, and our willingness to give back to American society.

See the article here:
Why is this nebula shaped like a butterfly? - Massive Science

Primary Cell Culture Market Size By Product Analysis, Application, End-Users, Regional Outlook, Competitive Strategies And Forecast Up To 2026 – 3rd…

New Jersey, United States,- Latest update on Primary Cell Culture Market Analysis report published with extensive market research, Primary Cell Culture Market growth analysis, and forecast by 2026. this report is highly predictive as it holds the overall market analysis of topmost companies into the Primary Cell Culture industry. With the classified Primary Cell Culture market research based on various growing regions, this report provides leading players portfolio along with sales, growth, market share, and so on.

The research report of the Primary Cell Culture market is predicted to accrue a significant remuneration portfolio by the end of the predicted time period. It includes parameters with respect to the Primary Cell Culture market dynamics incorporating varied driving forces affecting the commercialization graph of this business vertical and risks prevailing in the sphere. In addition, it also speaks about the Primary Cell Culture Market growth opportunities in the industry.

Primary Cell Culture Market Report covers the manufacturers data, including shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including Primary Cell Culture market size, volume and value, as well as price data.

Primary Cell Culture Market competition by top Manufacturers:

Primary Cell Culture Market Classification by Types:

Primary Cell Culture Market Size by End-user Application:

Listing a few pointers from the report:

The objective of the Primary Cell Culture Market Report:

Cataloging the competitive terrain of the Primary Cell Culture market:

Unveiling the geographical penetration of the Primary Cell Culture market:

The report of the Primary Cell Culture market is an in-depth analysis of the business vertical projected to record a commendable annual growth rate over the estimated time period. It also comprises of a precise evaluation of the dynamics related to this marketplace. The purpose of the Primary Cell Culture Market report is to provide important information related to the industry deliverables such as market size, valuation forecast, sales volume, etc.

Major Highlights from Table of contents are listed below for quick lookup into Primary Cell Culture Market report

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Our Trending Reports

Stem Cell Therapy Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Influenza Diagnostics Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Biomarkers Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

3D Bioprinting Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Cholesterol Screening-Cholesterol Lab Testing Services Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Originally posted here:
Primary Cell Culture Market Size By Product Analysis, Application, End-Users, Regional Outlook, Competitive Strategies And Forecast Up To 2026 - 3rd...

Precision Cancer Therapies Market 10-year Forecast and Trends Analysis Research Report – Jewish Life News

Global Precision Cancer Therapies Market report is a meticulous comprehensive analysis of this marketplace which provides access to direct firsthand insights on the expansion path of marketplace at near term and long term. On the grounds of factual advice sourced from real industry pros and extensive main business study, the report provides insights about the historical growth pattern of Precision Cancer Therapies Market and present market situation. It then provides brief and long-term market development projections.

Projections are only based on the comprehensive analysis of essential Market dynamics which are predicted to affect Precision Cancer Therapies Market performance and also their seriousness of influencing market growth within the span of assessment interval.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.researchmoz.com/enquiry.php?type=S&repid=2640383&source=atm

Along with evaluation of dynamics, the report supplies In-depth evaluation of key business trends that are anticipated to behave more prominently in global Precision Cancer Therapies Market. The analysis also provides valued information concerning the present and forthcoming growth opportunities in Precision Cancer Therapies Market the important players and new market entrants can capitalize on.

Competitive Businesses And Players in global market

The key players covered in this study Abbott Laboratories Bayer HealthCare GlaxoSmithKline OncoGenex Pharmaceuticals Hospira Boehringer Ingelheim AstraZeneca Aveo Pharmaceuticals

Market segment by Type, the product can be split into Hormone Therapy Immunotherapies Targeted Therapy Monoclonal Antibody Therapy Gene Therapy Market segment by Application, split into Hospitals Diagnostic Centers Oncology Clinics Research Institutes

Market segment by Regions/Countries, this report covers North America Europe China Japan Southeast Asia India Central & South America

The study objectives of this report are: To analyze global Precision Cancer Therapies status, future forecast, growth opportunity, key market and key players. To present the Precision Cancer Therapies development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America. To strategically profile the key players and comprehensively analyze their development plan and strategies. To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Precision Cancer Therapies are as follows: History Year: 2015-2019 Base Year: 2019 Estimated Year: 2020 Forecast Year 2020 to 2026 For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2640383&source=atm

Opportunity evaluation provided in the Precision Cancer Therapies Market report Is important concerning understanding the profitable regions of investment, which are the technical insights for major market players, providers, vendors, and other stakeholders in Precision Cancer Therapies Market.

Report offers detailed insights about each of the market sections and their sub-segments, which can be categorized based on par various parameters. An exhaustive regional evaluation of Global Precision Cancer Therapies Market divides Global marketplace landscape into essential geographies.

Regional prognosis and country-wise evaluation of Precision Cancer Therapies Market Allows for the analysis of multi-faceted operation of marketplace in all of the crucial markets. This advice plans to provide a wider reach of report to readers and establish the most applicable profitable areas in global market place.

Taxonomy and geographic analysis of the Global Precision Cancer Therapies Market empowers readers to see profits in present chances and catch forthcoming growth chances even until they approach the market location. The study given in report is only meant to unroll the economical, societal, regulatory and political situations of this marketplace specific to each area and nation, which might help prospective market entrants in Precision Cancer Therapies Market landscape to comprehend the nitty-gritty of target market regions and invent their plans accordingly.

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2640383&licType=S&source=atm

Major TOC Covered In this Report are:

Go here to read the rest:
Precision Cancer Therapies Market 10-year Forecast and Trends Analysis Research Report - Jewish Life News